JP Morgan analysts believe Ogsiveo's broad label is an outright victory for SpringWorks. They see the drug's global blockbuster potential and notice the company's research into its applicability to certain ovarian tumors and multiple myeloma.
$SpringWorks Therapeutics(SWTX.US)$SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors 1 MINUTE AGO, 6:04 PM EST VIA GLOBENEWSWIRE
Gainers: •$SpringWorks Therapeutics(SWTX.US)$+19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial ) •$Roivant Sciences(ROIV.US)$+7.1% (FDA has approved VTAMA (tapinarof) cream) •$Ocugen(OCGN.US)$+5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart) •$Skyline(SKY.US)$+4.4% (In reaction to earnings) •$網易(NTES.US)$+4.1% (In...
SpringWorks Therapeutics股票討論區
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA生物科學(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...
In reaction to earnings/guidance:
• $富樂客(FL.US)$ +19.7%, $BILL Holdings(BILL.US)$ +18.1% (also names new COO), $巴克爾(BKE.US)$ +1.7%
Other news:
• $Axsome Therapeutics(AXSM.US)$ +33.8% (announces FDA approval of AUVELITY the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults)
• $SpringWorks Therapeutics(SWTX.US)$ +4.9% (late-breaking oral presentation of phase 3 DeFi da...
• $紅羅賓(RRGB.US)$ +13.8% (In reaction to earnings)
• $PMV Pharmaceuticals(PMVP.US)$ +11.2% (ASCO-related announcement)
• $Sumo Logic(SUMO.US)$ +10.8% (In reaction to earnings)
• $艾切托(ACET.US)$ +9.6% (ASCO-related announcement)
• $戴爾科技(DELL.US)$ +9.6% (In reaction to earnings)
• $ImmunoGen(IMGN.US)$ +8.7% (ASCO-related announcement)
• $Ulta美容(ULTA.US)$ +7.9% (In reaction to earnings)
• $Zymergen(ZY.US)$ +7.8% (to...
• $SpringWorks Therapeutics(SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences(ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen(OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Skyline(SKY.US)$ +4.4% (In reaction to earnings)
• $網易(NTES.US)$ +4.1% (In...
暫無評論